- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
White House Reverses $10B in Cuts to ACA Cost-Sharing Subsidies
The White House has decided to reverse roughly $10 billion in cuts to the cost-sharing subsidies that were part of the Patient Protection and Affordable Care Act. That program was originally expected to be slashed by 7.3 % in fiscal 2015 and beyond as part of the sequester cuts.
The White House has decided to reverse roughly $10 billion in cuts to the cost-sharing subsidies that were part of the Patient Protection and Affordable Care Act. That program was originally expected to be slashed by 7.3 % in fiscal 2015 and beyond as part of the sequester cuts.
But in a report released this week by the Office of Management and Budget—and first flagged by the Committee for a Responsible Federal Budget—the Obama administration didn't include the cost-sharing subsidies among the programs that will be subject to the sequester cuts. That's a reversal from the previous year.
The cost-sharing subsidies get less attention than the tax credits, which are available to individuals making up to 400% of the federal poverty level to purchase plans through the state and federal exchanges. The subsidies are intended to help low-income individuals cover co-payments, deductibles and other out-of-pocket costs. They are available to individuals with incomes up to 250% of the federal poverty level who purchase plans that are designed to cover at least 70% of their medical costs.
Read the full story here: http://bit.ly/1gwvQcG
Source: Modern Healthcare
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Neurologists Share Tips for Securing Patient Access to Gene Therapies
March 19th 2025Tenacious efforts at every level, from the individual clinician to the hospital to the state to Congress, will be needed to make sure patients can access life-saving gene therapies for neuromuscular diseases.
Read More
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
